ArticleBMC cancer2026
Systematic transcriptomic analysis of UDP-glucuronosyltransferases reveals UGT2B11 as a diagnostic and metabolic marker in hepatocellular carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is characterized by profound metabolic reprogramming and immune heterogeneity, yet transcriptomic markers that reflect tumor-specific metabolic states remain limited. UDP-glucuronosyltransferases (UGTs) are key hepatic enzymes involved in detoxification and glucuronidation, but their systematic transcriptional landscape and clinical relevance in HCC have not been comprehensively explored. Here, we performed a comprehensive multi-cohort transcriptomic analysis of all 19 functional UGT family genes across TCGA-LIHC, GepLiver, GEPIA3, HCCDB, and an independent institutional cohort. Across datasets, most UGT genes exhibited global transcriptional downregulation with minimal genomic alterations, indicating that dysregulated expression rather than structural variation predominates in HCC. Among them, UGT2B11 uniquely demonstrated consistent upregulation, a markedly higher proportion of high-expression cases, and reproducible diagnostic performance across multiple cohorts. In the GepLiver and institutional cohorts, UGT2B11 expression was significantly elevated in HCC compared with normal and adjacent liver tissues, yielding area-under-the-curve values ranging from 0.79 to 0.84. Pathway enrichment analyses of genes correlated with UGT2B11 revealed strong enrichment of glucuronidation-related pathways, consistent with canonical UGT function, while also identifying mTORC1 signaling as a recurrent transcriptional feature modestly associated with UGT2B11 expression. Single-cell RNA-sequencing analyses demonstrated that UGT2B11 expression is largely confined to malignant hepatocyte populations, supporting its tumor-specific transcriptional activation. In parallel, immune infiltration analyses revealed significant positive associations between UGT2B11 expression and multiple immune cell signatures, most prominently Tregs, further supported by correlations with established Treg-associated genes. Collectively, this study delineates the transcriptomic landscape of the UGT family in HCC and identifies UGT2B11 as a tumor-associated metabolic transcript with reproducible diagnostic potential, while showing modest associations with mTORC1-related transcriptional programs and immune features.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.